Informed consent forms are overwhelming for patients. They are written at a level that is too high for most patients, thus possibly impeding real informed consents, according to a report given today at the IASLC World Conference ...
Aug 9, 2022
0
8
Cystic fibrosis remains an incurable genetic disorder that impairs lung function and significantly reduces life expectancy. A new combination drug therapy that addresses the disorder's underlying defects offers a promising ...
Aug 8, 2022
0
13
Following concurrent chemoradiation for unresectable stage III non-small cell lung cancer, both nivolumab alone and nivolumab and ipilimumab combined demonstrated improved 18- month progression-free survival compared with ...
Aug 8, 2022
0
5
An interim analysis of overall survival data from the IMpower010 trial showed an overall survival trend in favor of atezolizumab in the PD-L1 TC > 1% stage II-IIIA population (OS HR, 0.71 [95% CI: 0.49, 1.03]), but not in ...
Aug 8, 2022
0
17
The use of Stereotactic Body Radiotherapy (SBRT) for patients with non-small cell lung cancer can reduce treatment disparities between White and Black patients, according to research presented today at the IASLC World Conference ...
Aug 8, 2022
0
2
The protocol used to screen and detect lung cancer in the NELSON Trial is more sensitive than the protocol used in the National Lung Cancer Screening Trial, particularly for early-stage cancers, according to research reported ...
Aug 8, 2022
0
2
Using sotorasib as a lead-in therapy with pembrolizumab or atezolizumab for patients with advanced KRAS p.G12C non-small cell lung cancer demonstrated durable clinical activity with lower rates of grade 3-4 treatment-related ...
Aug 8, 2022
0
8
The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non-small cell lung cancer without disease progression after either concurrent chemoradiotherapy ...
Aug 8, 2022
0
2
A study presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna disclosed the clinical-relevant intertumoral heterogeneity of non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping.
Aug 8, 2022
0
5
Northwestern Medicine scientists have discovered a potential therapeutic target in the donor lung that can prevent primary graft dysfunction (PGD) in lung transplant recipients, according to findings published in the Journal ...
Aug 3, 2022
0
17
